NEW DRUG COSTS for R&D since about 2000 by US Pharma companies sum to approximately 650 Billion USD, or 50-70 Bn USD annually. In addition, there has been less bang for the buck, as efficacy rates have slid south towards placebo. In contrast, VCs spend about 8-10 Bn USD annually on all sectors, with Biopharma being a part of that pie. Thus, for the ~900 new drugs (not NCEs) over that time period, the well over 7X annual spend by Big Pharma can be seen as squandered capital. It is a fortunate thing that most Big Pharma are experimenting with outsourcing/licensing their pipeline stuffers.
http://lnkd.in/nYrdrN
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022